CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
已撤回：关注声明：“联合 4-1BB 和 ICOS 共刺激提高双抗 CD19/CD20CAR-T 细胞的抗肿瘤效能和持久性” [Cytotherapy, 第 23 卷，第 8 期，2021 年，715-723]
英文原题：WITHDRAWN: Expression of concern: "Combined 4-1BB and ICOS co-stimulation improves anti-tumor efficacy and persistence of dual anti-CD19/CD20 chimeric antigen receptor T cells" [Cytotherapy, Volume 23, Issue 8, 2021, 715-723].
查看英文原题
WITHDRAWN: Expression of concern: "Combined 4-1BB and ICOS co-stimulation improves anti-tumor efficacy and persistence of dual anti-CD19/CD20 chimeric antigen receptor T cells" [Cytotherapy, Volume 23, Issue 8, 2021, 715-723].
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
本文已应作者和/或编辑的要求撤回。出版商对由此可能造成的不便深表歉意。完整的 Elsevier 文章撤回政策可在 https://www.elsevier.com/about/policies/article-withdrawal 查阅。
展开英文摘要原文
This article has been withdrawn at the request of the author(s) and/or editor. The Publisher apologizes for any inconvenience this may cause. The full Elsevier Policy on Article Withdrawal can be found at https://www.elsevier.com/about/policies/article-withdrawal.
论文信息
- 文献类型
- 撤稿声明 · 已撤稿 · 关注声明
- 期刊
- Cytotherapy2024 Aug 10
- 原文标识
- PubMed 39985542 · DOI 10.1016/j.jcyt.2023.09.004